In summary, we propose a cDC1‐based in situ vaccine strategy that, in combination with tumor stemness inhibition, can potently activate CTLs mediated immune response and diminish tumor immune tolerance, enhancing the efficacy of tumor therapy. This evidence concerns the gene MPPE1 and neoplasm.